Improta, Luca http://orcid.org/0000-0002-8915-1168
Pasquali, Sandro
Iadecola, Sara
Barisella, Marta
Fiore, Marco
Radaelli, Stefano
Colombo, Chiara
Alloni, Rossana
Callegaro, Dario
Valeri, Sergio
Miceli, Rosalba
Gronchi, Alessandro
Funding for this research was provided by:
Ministero della Salute (Accelerator Award 2019-24297, FRRB-584-797, 60, GR-2019-12369175, Institutional grant BRI2017 from Fondazione IRCCS)
Università Campus Bio-Medico di Roma (Sarcoma Research Fund)
5x1000 Founds (2016)
Article History
Received: 7 September 2022
Accepted: 16 February 2023
First Online: 17 March 2023
Disclosure
: A.G. received compensation for Ad Boards from Novartis, Bayer, Lilly, PharmaMar, and SpringWorks, as well as honoraria from PharmaMar and Deciphera and research grants from PharmaMar and Nanobiotix. The other authors have declared that no competing interests exist.
: The study was approved by the Ethics Committee of Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy (INT 88/17).